NCT03459040View on ClinicalTrials.gov

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 17, 2018

Primary Completion Date

August 21, 2020

Study Completion Date

August 21, 2020

Conditions
Graft-versus-host-diseaseGVHD
Interventions
DRUG

Alpha 1-Antitrypsin

AAT will be given either in the hospital or the outpatient clinic two times per week.

Trial Locations (5)

10029

Icahn School of Medicine at Mount Sinai, New York

37232

Vanderbilt University, Nashville

43210

Ohio State University, Columbus

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

John Levine

OTHER

NCT03459040 - A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD | Biotech Hunter | Biotech Hunter